• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Actelion, Sanofi in talks after J&J backs out of negotiations

December 14, 2016 By Sarah Faulkner

Actelion, Sanofi in talks after J&J backs out of negotiationsActelion (VTX:ATLN) and Sanofi (NYSE:SNY) are reportedly in talks to reach a takeover deal after Johnson & Johnson (NYSE:JNJ) said yesterday that it has closed negotiations with the Swiss biotech. J&J and Actelion have been in informal talks for nearly 2 months and the US company has made an offer valued at 250 Swiss francs per share.

J&J said yesterday that it “was not able to reach an agreement that it believed would create adequate value for its shareholders.” Actelion told the company that it could attract offers that are significantly higher than the one made by J&J, according to Reuters. 

After J&J abandoned its efforts, Sanofi has stepped in to pursue negotiations. The French drugmaker is eager to land a deal, since it lost a bid for Medivation to Pfizer’s $14 billion offer in August. Analysts told Reuters that Sanofi CEO Olivier Brandicourt cannot afford to fail in a 2nd high-profile bid.

Analysts have previously suggested Sanofi could be a potential buyer, especially since Actelion’s portfolio of treatments for pulmonary arterial hypertension would complement Sanofiy’s Genzyme rare disease unit. But some are warning that J&J’s exit and a competitive bidding war could artificially drive up Actelion’s price.

“Winning a bidding war when it comes to acquiring biopharmaceutical companies almost always equates to way over-paying,” wrote Bernstein analyst Tim Anderson, according to Reuters.

“These are not bragging rights,” he said. “If Actelion were to go out at around $30 billion, this equates to around 13 times sales and 30 times earnings before interest and taxes. These are high figures.”

In the midst of competitive takeover offers is Actelion CEO Jean-Paul Clozel, who has repeatedly asserted the company’s independence. In 2011, he rallied shareholders against a hedge fund’s effort to sell the biotech firm.

“It wasn’t about price, he simply doesn’t want to give up control,” a source close to J&J told the news outlet.

ATLN shares were trading at 191.30 Swiss francs this morning, down -8.3%.

Filed Under: Featured, Mergers & Acquisitions, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Sanofi-Aventis

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS